| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6ee6e601667684611603458b8414417 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2750-14132 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate |
2021-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_939775372aeca263055678e8549e7ea4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8cfce887e3e9f5cbe3064b2a8b17cee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a726428562ffdc3a101eb25bff1376
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1913700c761027f877ae01032d14a020 |
| publicationDate |
2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021216503-A1 |
| titleOfInvention |
Aav delivery system for lung cancer treatment |
| abstract |
The disclosure provides a polynucleotide comprising: a first DNA sequence encoding a guide RNA (gRNA), wherein the gRNA comprises a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, and the DNA-binding domain is complementary to a target sequence in an NRF2 gene; and a first promoter that is operably linked to the DNA sequence. The disclosure also provides vectors (e.g. AAV vectors), recombinant AAV (rAAV) and pharmaceutical compositions comprising the polynucleotides described herein. The disclosure further provides a method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a polynucleotide, vector, rAAV or pharmaceutical composition as described herein to the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023091696-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023154451-A1 |
| priorityDate |
2020-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |